Advanced search×


Electronic ISSN

  1. Functional analysis of MKP-1 and MKP-2 in breast cancer tamoxifen sensitivity.

    Oncotarget 5(4):1101 (2014) PMID 24658355

    We examined the expression of Mitogen-Activated Protein Kinase Phosphatases (MKPs) 1 and 2 following tamoxifen treatment and the effects of MKP-1/MKP-2 overexpression on tamoxifen sensitivity. Treatment of MCF7 breast cancer cells with tamoxifen increased MKP-2, but not MKP-1, protein levels. Overex...
  2. Chloroquine synergizes with FTS to enhance cell growth inhibition and cell death.

    Oncotarget 5(1):173 (2014) PMID 24368422 PMCID PMC3960199

    We have shown that Ras inhibition by FTS induces autophagy, which partially protects cancer cells and may limit the use of FTS as an anti-cancer drug. Since FTS is a non toxic drug we hypothesized that FTS and chloroquine (an autophagy inhibitor) will synergize in cell growth inhibition and cell dea...
  3. MYC and MiR: vicious circle.

    Oncotarget 4(12):2168 (2013) PMID 24318653 PMCID PMC3926816

  4. HOXA11 hypermethylation is associated with progression of non-small cell lung cancer.

    Oncotarget 4(12):2317 (2013) PMID 24259349 PMCID PMC3926829

    This study was aimed at understanding the functional significance of HOXA11 hypermethylation in non-small cell lung cancer (NSCLC). HOXA11 hypermethylation was characterized in six lung cancer cell lines, and its clinical significance was analyzed using formalin-fixed paraffin-embedded tissues from...
  5. Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer.

    Oncotarget 4(12):2419 (2013) PMID 24293458 PMCID PMC3926837

    We hypothesized that BET inhibitors will regulate MYC expression in solid tumors that frequently over-express MYC. Here we describe the effects of the highly specific BET inhibitor, I-BET762, on MYC expression in prostate cancer models. I-BET762 potently reduced MYC expression in prostate cancer cel...
  6. FOXD3 is a novel tumor suppressor that affects growth, invasion, metastasis and angiogenesis of neuroblastoma.

    Oncotarget 4(11):2021 (2013) PMID 24269992 PMCID PMC3875767

    We report that FOXD3 is an important oncosuppressor of NB tumorigenicity and aggressiveness. We found that FOXD3 was down-regulated in NB tissues and cell lines. Patients with high FOXD3 expression have greater survival probability. Over-expression or knockdown of FOXD3 responsively altered both the...
  7. p53 regulates the transcription of the anti-inflammatory molecule developmental endothelial locus-1 (Del-1).

    Oncotarget 4(11):1976 (2013) PMID 24192518 PMCID PMC3875763

    Developmental endothelial locus-1 (Del-1) is an endothelium-derived anti-inflammatory molecule that is downregulated by inflammatory stimuli. Little is known about the molecular mechanisms by which Del-1 transcription is regulated. In the present study, a DNA sequence upstream of the Del-1 gene was...
  8. The deubiquitinating enzyme USP17 is associated with non-small cell lung cancer (NSCLC) recurrence and metastasis.

    Oncotarget 4(10):1836 (2013) PMID 24123619 PMCID PMC3858568

    USP17 is a cell cycle regulated deubiquitinating enzyme that is highly expressed in tumor-derived cell lines and has an established role in cell proliferation and chemotaxis. This is the first study to examine the clinical significance of USP17 expression in non-small cell lung cancer (NSCLC). USP17...
  9. CXXC5 (retinoid-inducible nuclear factor, RINF) is a potential therapeutic target in high-risk human acute myeloid leukemia.

    Oncotarget 4(9):1438 (2013) PMID 23988457 PMCID PMC3824541

    We investigated CXXC5/RINF expression in primary human acute myeloid leukemia (AML) cells derived from 594 patients, and a wide variation in CXXC5/RINF mRNA levels was observed both in the immature leukemic myeloblasts and in immature acute lymphoblastic leukemia cells. Furthermore, patients with lo...
  10. Myeloablative anti-CD20 radioimmunotherapy +/- high-dose chemotherapy followed by autologous stem cell support for relapsed/refractory B-cel...

    Oncotarget 4(6):899 (2013) PMID 23765188 PMCID PMC3757247

    We performed a phase I/II trial to assess feasibility and survival. Twenty-three patients with relapsed/refractory NHL without complete remission (CR) to salvage chemotherapy were enrolled to evaluate RIT with Iodine-131 labelled rituximab (131I-rituximab) in a myeloablative setting. Biodistribution...